{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:59:27Z","timestamp":1790369967367,"version":"4.1.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40265-026-02361-7","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T01:47:42Z","timestamp":1785808062000},"page":"1747-1751","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Lunsotogene Parvec: First Approval"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-7260-8131","authenticated-orcid":false,"given":"Aisling","family":"McGuigan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"10","key":"2361_CR1","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s00439-023-02595-5","volume":"142","author":"CL Ford","year":"2023","unstructured":"Ford CL, Riggs WJ, Quigley T, et al. The natural history, clinical outcomes, and genotype-phenotype relationship of otoferlin-related hearing loss: a systematic, quantitative literature review. Hum Genet. 2023;142(10):1429\u201349.","journal-title":"Hum Genet"},{"issue":"3","key":"2361_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/nrneurol.2016.10","volume":"12","author":"T Moser","year":"2016","unstructured":"Moser T, Starr A. Auditory neuropathy\u2014neural and synaptic mechanisms. Nat Rev Neurol. 2016;12(3):135\u201349.","journal-title":"Nat Rev Neurol"},{"key":"2361_CR3","unstructured":"Lustig L, Bance M, Ishiyama A, et al. Intracochlear administration of DBOTO gene therapy in pediatric patients with profound hearing loss due to otoferlin mutations: the CHORD phase 1\/2 open-label trial [abstract no. 10]. Mol Ther. 2024;32(4 Suppl. 1):6."},{"issue":"4","key":"2361_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.omtm.2025.101577","volume":"33","author":"Y Chung","year":"2025","unstructured":"Chung Y, Koehler SD, Cancelarich S, et al. Functional, sustained recovery of hearing in otoferlin-deficient mice using DB-OTO, a hair-cell-specific AAV-based gene therapy. Mol Ther Methods Clin Dev. 2025;33(4):1\u201318.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"10481","key":"2361_CR5","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(25)00248-X","volume":"405","author":"J Qi","year":"2025","unstructured":"Qi J, Xu L, Zeng FG, et al. OTOF-related gene therapy: a new way but a long road ahead. Lancet. 2025;405(10481):777\u20139.","journal-title":"Lancet"},{"key":"2361_CR6","unstructured":"Decibel Therapeutics. Decibel Therapeutics receives FDA clearance of IND application for DB-OTO, a gene therapy product candidate designed to provide hearing to individuals with otoferlin-related hearing loss [media release]. 17 Oct 2022. https:\/\/www.biospace.com\/."},{"key":"2361_CR7","unstructured":"Decibel Therapeutics. Decibel Therapeutics announces exclusive licensing agreements for hearing loss gene therapy technology [media release]. 2 Nov 2020. https:\/\/www.biospace.com\/."},{"issue":"10","key":"2361_CR8","doi-asserted-by":"publisher","first-page":"4496","DOI":"10.1073\/pnas.1817537116","volume":"116","author":"O Akil","year":"2019","unstructured":"Akil O, Dyka F, Calvet C, et al. Dual AAV-mediated gene therapy restores hearing in a DFNB9 mouse model. Proc Natl Acad Sci USA. 2019;116(10):4496\u2013501.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2361_CR9","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201809396","author":"H Al-Moyed","year":"2019","unstructured":"Al-Moyed H, Cepeda AP, Jung S, et al. A dual-AAV approach restores fast exocytosis and partially rescues auditory function in deaf otoferlin knock-out mice. EMBO Mol Med. 2019. https:\/\/doi.org\/10.15252\/emmm.201809396.","journal-title":"EMBO Mol Med"},{"key":"2361_CR10","unstructured":"U.S. Food & Drug Administration. FDA approves first-ever gene therapy for treatment of genetic hearing loss under national priority voucher program [media release]. 23 Apr 2026. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-ever-gene-therapy-treatment-genetic-hearing-loss-under-national-priority-voucher."},{"key":"2361_CR11","unstructured":"Regeneron Pharmaceuticals. OTARMENI\u2122 (lunsotogene parvec-cwha) suspension, for intracochlear infusion: US prescribing information. 2026. https:\/\/www.regeneron.com\/downloads\/otarmeni_fpi.pdf. Accessed 30 Jun 2026."},{"key":"2361_CR12","unstructured":"Regeneron Pharmaceuticals. Otarmeni\u2122 (lunsotogene parvec-cwha) approved by FDA as first and only gene therapy for genetic hearing loss; Regeneron to provide Otarmeni for free in the U.S [media release]. 23 Apr 2026. http:\/\/www.regeneron.com\/."},{"key":"2361_CR13","unstructured":"U.S. Food & Drug Administration. OTARMENI: summary basis for regulatory action. 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/otarmeni. Accessed 30 Jun 2026."},{"key":"2361_CR14","unstructured":"Decibel Therapeutics. Decibel Therapeutics receives European Orphan Drug designation for lead gene therapy candidate DB-OTO [media release]. 30 Mar 2023. https:\/\/www.biospace.com\/."},{"key":"2361_CR15","unstructured":"Regeneron Pharmaceuticals. Regeneron completes acquisition of Decibel Therapeutics, adding promising gene therapy programs for hearing loss [media release]. 25 Sep 2023. http:\/\/www.regeneron.com\/."},{"key":"2361_CR16","unstructured":"Regeneron Pharmaceuticals, Decibel Therapeutics. Regeneron and Decibel Therapeutics announce strategic collaboration to discover and develop therapeutics for hearing loss and tinnitus [media release]. 29 Nov 2017. http:\/\/www.regeneron.com\/."},{"key":"2361_CR17","unstructured":"Decibel Therapeutics. Decibel Therapeutics announces extension of research term under strategic collaboration with Regeneron to discover and develop gene therapies for hearing loss [media release]. 22 Nov 2021. https:\/\/www.biospace.com\/."},{"key":"2361_CR18","unstructured":"U.S. Securities And Exchange Commission. 2023. https:\/\/www.sec.gov\/ix?doc=\/Archives\/edgar\/data\/1656536\/000095017023007849\/dbtx-20221231.htm. Accessed 30 Jun 2026."},{"key":"2361_CR19","unstructured":"Decibel Therapeutics. Decibel and Catalent sign development and manufacturing agreement for dual-vector gene therapy for the treatment of congenital hearing loss [media release]. 4 Feb 2021. https:\/\/biologics.catalent.com\/catalent-news\/decibel-and-catalent-sign-development-and-manufacturing-agreement-for-dual-vector-gene-therapy-for-the-treatment-of-congenital-hearing-loss\/."},{"issue":"11","key":"2361_CR20","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1056\/NEJMoa2400521","volume":"394","author":"V Valayannopoulos","year":"2026","unstructured":"Valayannopoulos V, Bance M, Carvalho DS, et al. DB-OTO gene therapy for inherited deafness. N Engl J Med. 2026;394(11):1074\u201383.","journal-title":"N Engl J Med"},{"key":"2361_CR21","unstructured":"U.S. Food & Drug Administration. OTARMENI: letters, reviews, and related documents. 9. Statistical review. 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/otarmeni. Accessed 30 Jun 2026."},{"key":"2361_CR22","unstructured":"U.S. Food & Drug Administration. OTARMENI: letters, reviews, and related documents. 8. Pharmacovigilance original BLA memorandum. 2026. https:\/\/www.fda.gov\/vaccines-blood-biologics\/otarmeni. Accessed 30 Jun 2026."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02361-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02361-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02361-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T20:04:30Z","timestamp":1790366670000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02361-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["2361"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02361-7","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"15 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Aisling McGuigan is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":1,"name":"Ethics","label":"Authorship and Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}}]}}